SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

Zim Integrated Shipping Services is trending as Hapag-Lloyd confirms a $35 per share acquisition, sparking community debate over the offer's valuation compared to ZIM's book value and potential for dividends before the deal's 2026 close, all while intensifying discussion around a significant short squeeze.

Kenvue, Inc. is a consumer health company, which engages in manufacturing and selling healthcare products which includes cosmetics, drugs, and medical devices. Its brands include Aveeno, BAND-AID Brand, Johnson’s, Listerine, Neutrogena, and Tylenol. It operates through the following segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment includes cough, cold and allergy, pain care, digestive health, and smoking cessation. The Skin Health and Beauty segment offers face and body care, and others. The Essential Health segment focuses on oral care, baby care, women's health, and wound care. The company was founded on February 23, 2022 and is headquartered in Summit, NJ.

Kenvue Inc

Kimberly-Clark's acquisition bid for Kenvue, valuing shares at $21.01, is driving significant arbitrage interest, even as community sentiment remains divided over ongoing Tylenol litigation and its potential impact on the deal and the acquiring company's outlook.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Celldex Therapeutics is trending following strong clinical data for its lead drug barzolvolimab in chronic urticaria, with the community anticipating it as a potential best-in-class treatment or buyout target despite ongoing discussions about its safety profile and long development timeline.

MasTec, Inc. engages in the provision of infrastructure construction services. It operates through the following segments: Communications, Oil and Gas, Clean Energy and Infrastructure, and Other. The Communications segment performs engineering, construction, maintenance, and customer fulfillment activities related to communications infrastructure, primarily for wireless and wireline/fiber communications, and install-to-the-home customers. The Oil and Gas segment offers services on oil and natural gas pipelines and processing facilities for the energy and utilities industries. The Clean Energy and Infrastructure segment serves energy, utility and other end-markets through the installation and construction of power generation facilities, including from clean energy and renewable sources such as wind, solar and biomass, as well as various types of heavy civil and industrial infrastructure. The Other segment consists of equity investors, other small business units that perform construction, and other services for a variety of international end-markets. The company was founded by Jorge Mas Canosa on July 26, 1968, and is headquartered in Coral Gables, FL.

Mastec Inc.

MasTec is capturing market attention with strong financial results and multiple analyst upgrades, positioning it as a key beneficiary of accelerating public infrastructure spending and the surging demand for AI-driven data center and power grid construction, prompting community discussions on its growth trajectory and premium valuation.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium (HNT) is trending as the community discusses its AT&T partnership for expanded Wi-Fi connectivity and the dismissal of its SEC lawsuit, with many anticipating a rally driven by these developments, institutional interest from a Grayscale trust, and tokenomics changes that consolidate rewards into HNT, despite ongoing skepticism from some regarding past performance.

Tidal Trust II - YieldMax HOOD Option Income Strategy ETF

YieldMax HOOD Option Income Strategy ETF

YieldMax HOOD Option Income Strategy ETF ($HOOY) is drawing significant attention due to its substantial weekly dividend payouts and a notable increase in institutional ownership. This is fueling an active community discussion about whether its high income stream sufficiently offsets concerns regarding potential long-term share price erosion, a characteristic often associated with covered call ETFs.

Olema Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of next generation targeted therapies for women’s cancers. Its product candidate, OP-1250, is a novel oral therapy with combined activity as both a complete ER antagonist, or CERAN, and a selective ER degrader, or SERD, which is believed to drive deeper, more durable responses than existing therapies. The company was founded by Cyrus L. Harmon and Peter J. Kushner on August 7, 2006 and is headquartered in San Francisco, CA.

Olema Pharmaceuticals Inc

Olema Pharmaceuticals is trending after positive Phase 3 data from Roche for a similar breast cancer drug ignited optimism for OLMA's lead asset, palazestrant. This has spurred upgraded analyst price targets and buyout speculation, though some investors are wary of insider selling and recent share offerings.

SiTime Corp.is a micro-electromechanical system-based silicon timing solution. The company is transforming the timing industry with configurable solutions that replace legacy quartz devices and enable customers to differentiate their products with performance, smaller size, lower power, and reliability. The company was founded by Markus Lutz and Aaron Partridge on December 3, 2003 and is headquartered in Santa Clara, CA.

SiTime Corp

SiTime is trending following strong financial results and a strategic acquisition in the precision timing business, which is eliciting bullish sentiment and analyst upgrades. The semiconductor company is frequently cited by the community as a vital "picks and shovels" play, with its MEMS timing technology considered the "heartbeat" for AI infrastructure and advanced technology sectors.

Renaissance Capital Greenwich Funds - Renaissance International IPO ETF

The Renaissance International IPO ETF ($IPOS) is garnering significant attention from retail investors, with sustained chatter across social media platforms discussing its performance and notable option activity. This ETF remains a focal point for those looking to gauge or capitalize on the dynamic landscape of international initial public offerings.

Codatta

Codatta ($XNY) is trending with strong community buzz, as it shows resilience against broader market pullbacks while traders anticipate a 'next leg' up. Its focus on powering AI and DeSci data projects, bolstered by an upcoming on-chain fingerprint verification feature, is driving conversations around potential new highs and breaking resistance levels.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Celldex Therapeutics Teases Key Barzolvolimab Phase 3 Updates, New Data at Guggenheim Summit

Celldex Therapeutics (NASDAQ:CLDX) executives used a presentation at the Guggenheim Emerging Outlook Biotech Summit 2026 to outline upcoming clinical milestones for barzolvolimab across multiple...

Celldex Therapeutics Breaks Below 200-Day Moving Average - Notable for CLDX

In trading on Thursday, shares of Celldex Therapeutics, Inc. (Symbol: CLDX) crossed below their 200 day moving average of $23.76, changing hands as low as $23.61 per share. Celldex Therapeutics, Inc...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the ten brokerages that are covering the company, MarketBeat.com...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Sees Large Growth in Short Interest

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the target of a large increase in short interest in the month of December. As of December 31st, there was short interest totaling...

Celldex Therapeutics (NASDAQ:CLDX) Trading Down 7.5% - Here's Why

Celldex Therapeutics (NASDAQ:CLDX) Stock Price Down 7.5% - Should You Sell...

Celldex Therapeutics SVPs Engage In Heavy Transactions

Key PointsFreddy A. Jimenez directly sold 4,166 shares for a transaction value of $121,210 on Dec. 4, 2025...

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of "Moderate Buy" by Analysts

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eleven research firms that are covering the stock, Marketbeat...

Celldex Therapeutics (NASDAQ:CLDX) Trading 4.1% Higher - Should You Buy?

Celldex Therapeutics (NASDAQ:CLDX) Shares Up 4.1% - Here's Why...

Simplify Asset Management Inc. Invests $2.20 Million in Celldex Therapeutics, Inc. $CLDX

Simplify Asset Management Inc. purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) during the third quarter, according to its most recent Form 13F filing with...

Short Interest in Celldex Therapeutics, Inc. (NASDAQ:CLDX) Declines By 20.9%

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Get Free Report) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling...

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

CLDX
Celldex Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLDX News

CLDXCelldex Therapeutics Inc.